<unk>  is indicated for the treatment of adults with multiple myeloma: * in combination with bortezomib, melphalan and prednisone (D-VMP) in newly diagnosed adults who are ineligible for autologous stem cell transplant * in combination with lenalidomide and dexamethasone (D-Rd) in newly diagnosed adults who are ineligible for autologous stem cell transplant and in people with relapsed or refractory multiple myeloma who have received at least one prior therapy * in combination with bortezomib and dexamethasone (D-Vd) in adults who have received at least one prior therapy * as monotherapy, in adults who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. In January 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to<unk>  in combination with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed amyloid light-chain amyloidosis. In November 2021, the FDA granted approval to<unk>  in combination with carfilzomib plus dexamethasone to treat relapsed or refractory multiple myeloma in adults who have received one to three prior lines of therapy.
Daratumumab/hyaluronidase
Pertuzumab/trastuzumab/hyaluronidase
Enfortumab vedotin
Peginterferon beta-1a
Peginterferon alfa-2a
Interferon beta-1a
Interferon beta-1b
Peginterferon alfa-2b